SHENZHEN-WOODY-VAPES
At 9:30pm (GMT +8) on November 12, ZOVOO, a new industry-leading atomization company, held its 2021 distributor conference online. Distributors from United States, United Kingdom, France and other countries participated in the conference. Meanwhile, ZOVOO also displayed its newly developed disposable products DRAGBAR series for the first time to the public, which attracted widespread attention from distributors worldwide.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211126005521/en/
Founded in 2010, ZOVOO has sophisticated research and develop capability, forward-looking product design and perfect supply chain system. ZOVOO founding team has 10 years of proven strength and experience. They have the absolute advantages in terms of heating materials, air channel structure design, etc., and build up the five criteria of good flavor. The birth of each product needs to go through from R&D, design, production, testing and so on. Every detail is perfect, only to bring a comfortable and safe experience. For example, the birth of each rich flavor comes from ZOVOO's five innovative concepts of sweet, soft, mellow, fragrant and powerful. ZOVOO researched 3,000 global users and pre-researched over 300 flavors to build its unique flavor nebula system.
ZOVOO is committed to building strategic partnerships with ICCPP manufacturers based on mutual trust. ZOVOO achieves sustainable supply chain management through support and cooperation in safety standards, social values and environmental sustainability. ZOVOO contributes to environmental sustainability by simplifying design, optimizing packaging, using new environmentally friendly materials, enhancing recycling, and reducing the environmental impact of the production process. In addition, it focuses on sensory preferences of users, which are translated into scientific indicators, production standards, and safety considerations to match different needs.
The upcoming DRAGBAR has three products, namely DRAGBAR 600, DRAGBAR 1000 and DRAGBAR 2200. DRAGBAR adopts the most popular double injection molding process and cleverly uses color collision to create a great-looking, great-taste and great-quality product. In response to consumer concerned problems, such as oil leakage and dry hit, ZOVOO has used polymer cotton and ergonomical design mouthpiece to solve them, while ensuring the taste and restoration of the product. DRAGBAR has ten different flavors, including lush ice, mango ice, grape ice and OMG, etc, which are popular in the market.
Not defined by labels, not bound by age. Dare to be unique, create something different, ZOVOO is born for this. In the future, ZOVOO will dedicate itself to improve the worldwide vapors’ experience and provides a alternative for smokers. Creating a new world with personality and spirit, ZOVOO will bring a different and great experience to global vapors.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211126005521/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom